Co-administration of miR-105–1 with kisspeptin holds promise in elevating the efficacy of kisspeptin-based treatments for ovulation induction in assisted reproduction, animal production, and the management of ovarian insufficiency. The gene discussed is KISS1; the disease is ovarian dysfunction.